Clinical trial · Observational
Refractory Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma After First-line Immuno-CT: Treatment Options and Outcomes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo). Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. The investigators performed a retrospective analysis, which included 104 DLBCL patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease. The investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Outcome according to pattern of refractoriness
- timeFrame
- Up to 4 years
- description
- OS was defined as the time from first relapse, or progression, to death from any cause.
Secondary outcomes (1)
- measure
- Outcome according to pattern of refractoriness
- timeFrame
- Up tp 24 months
- description
- EFS was defined as the time from first relapse, or progression, to the next event (defined as either second relapse/progression, change of therapy, or death from any cause). Patients who did not experience an event were censored at the last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: -≥18 years of age * diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017 * presented with refractory disease in response to front-line therapies * including anthracycline-based chemo and a monoclonal anti-CD20 antibody Exclusion Criteria: * Patients with a history of indolent lymphoma, * Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma
References
Publications (0)
Data not yet available